STOCK TITAN

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

NeuroBo Pharmaceuticals (Nasdaq: NRBO) has signed an exclusive license agreement with MThera Pharma for NB-01, a potential treatment for painful diabetic neuropathy. The agreement grants MThera rights to conduct research and clinical trials, including a possible Phase 3 trial in the US and South Korea. This move aligns with NeuroBo's strategy to out-license legacy assets and focus on developing DA-1726 and DA-1241.

MThera, with its expertise in natural medicines and botanical drugs, plans to utilize its SyMthomics platform to identify NB-01's mechanism of action and active ingredients. This approach aims to predict clinical efficacy and advance NB-01 into further clinical development, building on its positive Phase 2 results for diabetic neuropathy.

NeuroBo Pharmaceuticals (Nasdaq: NRBO) ha firmato un accordo di licenza esclusivo con MThera Pharma per NB-01, un potenziale trattamento per neuropatia diabetica dolorosa. L'accordo concede a MThera i diritti per condurre ricerche e studi clinici, inclusa una possibile fase 3 negli Stati Uniti e in Corea del Sud. Questa mossa si allinea con la strategia di NeuroBo di cessione di beni legacy e di concentrarsi sullo sviluppo di DA-1726 e DA-1241.

MThera, grazie alla sua esperienza in farmaci naturali e botanici, prevede di utilizzare la propria piattaforma SyMthomics per identificare il meccanismo d'azione di NB-01 e i suoi principi attivi. Questo approccio mira a prevedere l'efficacia clinica e a far progredire NB-01 in ulteriori sviluppi clinici, basandosi sui suoi risultati positivi della fase 2 per la neuropatia diabetica.

NeuroBo Pharmaceuticals (Nasdaq: NRBO) ha firmado un acuerdo de licencia exclusiva con MThera Pharma para NB-01, un tratamiento potencial para neuropatía diabética dolorosa. El acuerdo otorga a MThera los derechos para realizar investigaciones y ensayos clínicos, incluida una posible fase 3 en EE. UU. y Corea del Sur. Este movimiento se alinea con la estrategia de NeuroBo de licenciar activos heredados y centrarse en el desarrollo de DA-1726 y DA-1241.

MThera, con su experiencia en medicamentos naturales y fármacos botánicos, planea utilizar su plataforma SyMthomics para identificar el mecanismo de acción de NB-01 y sus ingredientes activos. Este enfoque tiene como objetivo predecir la eficacia clínica y avanzar NB-01 a un mayor desarrollo clínico, basándose en sus resultados positivos de la fase 2 para la neuropatía diabética.

NeuroBo Pharmaceuticals (Nasdaq: NRBO)는 통상 라이센스 계약을 MThera Pharma와 체결하여 NB-01을 확보했습니다. 이는 통증성 당뇨병성 신경병증을 위한 잠재적 치료제입니다. 계약은 MThera에게 연구 및 임상 시험을 실시할 권한을 부여하며, 여기에는 미국과 한국에서의 3상 시험이 포함될 수 있습니다. 이러한 조치는 NeuroBo가 구식 자산의 아웃 라이센스 및 DA-1726과 DA-1241의 개발에 집중하는 전략과 일치합니다.

MThera는 천연 약물 및 식물 약물에 대한 전문성을 바탕으로 SyMthomics 플랫폼을 활용하여 NB-01의 작용 메커니즘 및 활성 성분을 식별할 계획입니다. 이 접근법은 임상 효능을 예측하고 NB-01을 추가 임상 개발로 진행하는 것을 목표로 하며, 당뇨병성 신경병증에 대한 2상 긍정적인 결과를 바탕으로 합니다.

NeuroBo Pharmaceuticals (Nasdaq: NRBO) a signé un accord de licence exclusif avec MThera Pharma pour NB-01, un traitement potentiel pour neuropathie diabétique douloureuse. Cet accord accorde à MThera le droit de mener des recherches et des essais cliniques, y compris un possible essai de phase 3 aux États-Unis et en Corée du Sud. Ce mouvement s'inscrit dans la stratégie de NeuroBo de licencier des actifs hérités et de se concentrer sur le développement de DA-1726 et DA-1241.

MThera, avec son expertise en médicaments naturels et en phytothérapie, prévoit d'utiliser sa plateforme SyMthomics pour identifier le mécanisme d'action de NB-01 et ses ingrédients actifs. Cette approche vise à prédire l'efficacité clinique et à faire progresser NB-01 vers un développement clinique plus avancé, en s'appuyant sur ses résultats positifs de phase 2 pour la neuropathie diabétique.

NeuroBo Pharmaceuticals (Nasdaq: NRBO) hat einen exklusiven Lizenzvertrag mit MThera Pharma für NB-01 unterzeichnet, ein potenzielles Behandlungsmittel für schmerzhafte diabetische Neuropathie. Der Vertrag gewährt MThera das Recht, Forschung und klinische Studien durchzuführen, einschließlich möglicher Phase-3-Studien in den USA und Südkorea. Dieser Schritt entspricht der Strategie von NeuroBo, Altvermögen zu lizenzieren und sich auf die Entwicklung von DA-1726 und DA-1241 zu konzentrieren.

MThera plant, mit seiner Expertise in natürlichen Heilmitteln und pflanzlichen Arzneimitteln die SyMthomics-Plattform zu nutzen, um den Wirkmechanismus von NB-01 und dessen aktive Inhaltsstoffe zu identifizieren. Dieser Ansatz zielt darauf ab, die klinische Wirksamkeit vorherzusagen und NB-01 in die weitere klinische Entwicklung voranzubringen, basierend auf den positiven Ergebnissen der Phase 2 für diabetische Neuropathie.

Positive
  • Exclusive license agreement signed for NB-01, potentially advancing its development
  • Alignment with NeuroBo's strategy to focus on core assets DA-1726 and DA-1241
  • Positive Phase 2 efficacy results for NB-01 in diabetic neuropathy
  • Potential for Phase 3 clinical trial in the US and South Korea
Negative
  • Financial terms of the agreement not disclosed
  • Out-licensing of NB-01 may reduce potential future revenue streams for NeuroBo

Insights

This exclusive licensing agreement between NeuroBo Pharmaceuticals and MThera Pharma for NB-01 is a strategic move that could have significant implications for both companies and the treatment of painful diabetic neuropathy.

The deal allows NeuroBo to streamline its focus on its core assets, DA-1726 and DA-1241, while potentially benefiting from future development of NB-01. This aligns with the company's stated strategy of out-licensing legacy assets, which could improve its financial position and resource allocation.

For MThera, acquiring rights to NB-01 expands their pipeline with a promising Phase 2 asset in the lucrative diabetic neuropathy market. Their expertise in natural medicines and botanical drugs, coupled with their SyMthomics platform, could potentially accelerate NB-01's development and increase its chances of success in Phase 3 trials.

However, investors should note that financial terms were not disclosed, making it difficult to assess the immediate impact on NeuroBo's balance sheet. The long-term value of this deal will depend on NB-01's performance in future clinical trials and its eventual commercialization prospects.

Overall, this agreement represents a calculated risk for both parties. If successful, it could lead to a valuable treatment option for diabetic neuropathy patients and significant returns for both companies. However, as with any drug development process, there are substantial risks and uncertainties ahead.

The licensing of NB-01 to MThera Pharma marks an interesting development in the field of diabetic neuropathy treatment. The positive Phase 2 efficacy results mentioned in the article are encouraging, but it's important to remember that many drugs fail in Phase 3 trials despite promising earlier results.

MThera's SyMthomics platform technology could be a game-changer in this context. By identifying the mechanism of action and active ingredients of NB-01, they may be able to optimize the drug's formulation or better predict its efficacy in larger patient populations. This could potentially increase the chances of success in Phase 3 trials.

However, it's important to note that botanical drugs often face unique challenges in regulatory approval processes. The FDA typically requires more extensive characterization and standardization for these products compared to synthetic drugs. MThera's experience in this area could be important in navigating these regulatory hurdles.

From a medical perspective, a new treatment for painful diabetic neuropathy would be welcome. Current treatments often have efficacy or significant side effects. If NB-01 can demonstrate a superior efficacy or safety profile in Phase 3 trials, it could potentially capture a significant market share.

Investors should keep a close eye on any announcements regarding the initiation of Phase 3 trials and their design, as these will be critical in determining the future prospects of NB-01.

CAMBRIDGE, Mass., July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the signing of an exclusive license agreement, providing MThera Pharma Co., Ltd. (MTHERA) with the rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of NB-01. Financial terms of the agreement were not disclosed.

"Finalizing this agreement for NB-01 is an important milestone for NeuroBo, reflecting our stated commitment to out-license our legacy assets in order to focus on the continued clinical development of DA-1726 and DA-1241," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "MTHERA has extensive experience in manufacturing, quality control and clinical development of natural medicines and botanical drugs, making the company an ideal partner to continue the development of NB-01."

"Based on the positive Phase 2 efficacy results for NB-01 for diabetic neuropathy, we intend to develop it as a potential treatment for peripheral diabetes," stated Dr. Mi Won Sohn, Chief Executive Officer of MTHERA. "Utilizing our SyMthomics platform technology, we can clearly identify the mechanism of action and active ingredients of NB-01 to assist in predicting its clinical efficacy as an innovative treatment, with the intent of advancing NB-01 into the next phase of clinical development. We are grateful to NeuroBo for the opportunity to further advance NB-01, and to potentially bring this promising therapy to patients in need."

About MThera Pharma
MThera Pharma Co., Ltd., headquartered in Seoul, South Korea, is a biopharmaceutical company developing first-in-class botanical drug products using novel, multi-component/multi-target-driven disease-modifying therapies to address diverse etiology and treat chronic incurable diseases such as Parkinson's disease, dementia and inflammatory bowel disease. MThera's platform technology, SyMthomics, consists of its MThera-CODA system (AI based in silico system), a cutting-edge multi-omics integration technology, as well as systems biology and bioinformatics. MThera's standardization technology and advanced CMC technology for raw materials, drug substances and drug products are designed to meet the U.S. Food and Drug Administration requirements for therapeutic consistency. For more information, please visit www.mtherapharma.com.

About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit www.neurobopharma.com.

Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with NeuroBo's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of NeuroBo's current and future product candidates, the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the cooperation of NeuroBo's contract manufacturers, clinical study partners and others involved in the development of NeuroBo's current and future product candidates; potential negative interactions between NeuroBo's product candidates and any other products with which they are combined for treatment; NeuroBo's ability to initiate and complete clinical trials on a timely basis; NeuroBo's ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to NeuroBo's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in NeuroBo's filings with the Securities and Exchange Commission, including NeuroBo's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. NeuroBo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

NeuroBo Pharmaceuticals 
Marshall H. Woodworth 
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com

Rx Communications Group 
Michael Miller 
+1 917-633-6086
mmiller@rxir.com 

Cision View original content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-announces-exclusive-license-agreement-with-mthera-pharma-for-nb-01-302208809.html

SOURCE NeuroBo Pharmaceuticals, Inc.

FAQ

What is the purpose of NeuroBo Pharmaceuticals' license agreement with MThera Pharma for NB-01?

The exclusive license agreement allows MThera Pharma to conduct research and clinical trials, including a potential Phase 3 trial, for NB-01 in the treatment of painful diabetic neuropathy, with the aim of future commercialization.

What were the results of NB-01's Phase 2 trial for diabetic neuropathy?

The press release mentions positive Phase 2 efficacy results for NB-01 in diabetic neuropathy, which has prompted MThera to pursue further development of the drug.

How does the NB-01 license agreement align with NeuroBo Pharmaceuticals' (NRBO) strategy?

The agreement aligns with NeuroBo's strategy to out-license legacy assets, allowing the company to focus on the clinical development of its core assets, DA-1726 and DA-1241.

What technology will MThera use to develop NB-01 further?

MThera plans to use its SyMthomics platform technology to identify NB-01's mechanism of action and active ingredients, aiming to predict its clinical efficacy and advance it to the next phase of clinical development.

NeuroBo Pharmaceuticals, Inc.

NASDAQ:NRBO

NRBO Rankings

NRBO Latest News

NRBO Stock Data

20.33M
3.00M
65.24%
12.71%
0.4%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE